Immuneering (IMRX) stock price is $3.81, up 4.30% on the day, as of Nov 10, 2026. It has a market cap of $246.36Mn, and is classified in the Pharmaceuticals industry (Healthcare sector).
Enterprise Value
Margins
P/FCF
Key Stats
Market Cap246.36 Mn
P/E-3.70
FCF (Yr)-45.49 Mn
ROA (Yr)-39.58
EV to EBIT5.12
Net Income (Yr)-56.02 Mn
Enterprise Value-378.47 Mn
Add ratio to table…
About
Immuneering Corp is a late stage clinical oncology company focused on developing and commercializing Deep Cyclic Inhibitors a novel class of anti cancer medicines. The company targets the mitogen activated protein kinase MAPK pathway and other core signaling pathways to improve durability and tolerability of cancer therapies. Its lead product candidate atebimetinib is an oral once daily inhibitor of MEK designed to provide cyclic inhibition of the MAPK pathway. Immuneering…
Immuneering Corp is a late stage clinical oncology company focused on developing and commercializing Deep Cyclic Inhibitors a novel class of anti cancer medicines. The company targets the mitogen activated protein kinase MAPK pathway and other core signaling pathways to improve durability and tolerability of cancer therapies. Its lead product candidate atebimetinib is an oral once daily inhibitor of MEK designed to provide cyclic inhibition of the MAPK pathway. Immuneering also advances a second clinical stage program called envometinib and conducts early discovery research on other signaling pathways.
Immuneering generates revenue primarily through fees for translational bioinformatics analyses performed for pharmaceutical and biotechnology partners. The company has provided services such as analyzing ibrutinib ipilimumab daratumumab glatiramer acetate and pridopidine for its collaborators. In addition Immuneering expects to receive license fees royalties or milestones if its product candidates advance to commercialization. Currently the company does not have product sales or a commercial distribution network.
Immuneering positions itself as an innovator in the oncology therapeutics space by pursuing a distinct mechanism called Deep Cyclic Inhibition that aims to normalize signaling dynamics rather than achieve chronic pathway blockade. The company faces competition from larger pharmaceutical firms developing traditional MEK inhibitors such as those marketed by Pfizer and Novartis as well as from biotechs pursuing KRAS directed therapies like Amgen and Mirati Therapeutics. Immuneering believes its proprietary bioinformatics platform and three dimensional tumor modeling give it a competitive edge in identifying drug candidates with improved efficacy and reduced toxicity.
Immuneering serves pharmaceutical and biotechnology companies that seek expertise in translational bioinformatics and tumor modeling. Specific partners mentioned in its filings include Johnson & Johnson for ibrutinib and daratumumab Bristol Myers Squibb for ipilimumab Teva for glatiramer acetate and Prilenia Therapeutics for pridopidine. The company also collaborates with Regeneron Pharmaceuticals on clinical supply of Libtayo and with Eli Lilly and Company on clinical supply of olomorasib.
Sector:HealthcareSector rationaleThe company's primary focus is the development of anti-cancer medicines, specifically its lead product candidate atebimetinib and other clinical-stage oncology programs. While its current revenue is generated through translational bioinformatics analyses for pharmaceutical partners, this activity serves as a bridge to its core goal of commercializing therapeutics, placing it firmly in Healthcare. A secondary sector of Technology is justified because the company sells its proprietary bioinformatics platform and analysis services as a distinct revenue-generating business line to external biotechnology and pharmaceutical customers.Industries:PharmaceuticalsPharmaceuticalsPrimaryImmuneering is a clinical oncology company developing branded prescription anti-cancer medicines, specifically its lead product candidate atebimetinib, an oral MEK inhibitor. The company's core business is the discovery and development of a novel class of medicines called Deep Cyclic Inhibitors.Contract ResearchContract ResearchSecondaryThe company generates current revenue by providing translational bioinformatics analyses and tumor modeling services for pharmaceutical and biotechnology partners such as Johnson & Johnson and Bristol Myers Squibb.Classified using BQ-MICSCIK: 0001790340
Peer percentiles
How Immuneering ranks
Ranked against the 671 companies in Pharmaceuticals and Biotechnology·58 metrics · as of Nov 6, 2026
Valuation
12 metrics · Lower multiples rank higher; a negative multiple ranks last